Compare Inovio Pharmaceuticals Inc (INO) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Nokia Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Nokia Corp trades at $10.71 (market cap $56.70B). The key difference: Nokia Corp is far larger — about 635.2× Inovio Pharmaceuticals Inc's market cap, and Nokia Corp pays a 1.63% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | NOK | |
|---|---|---|
Market Cap | $89.27M | $56.70B |
Sector | Health | Technology |
52-Week High | $2.87 | $16.83 |
52-Week Low | $1.05 | $4.05 |
Enterprise Value | $60.28M | $53.51B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Nokia (NOK) trades at $10.115, down 0.05% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed Q1 2026 earnings, missing EPS estimates, but has beaten expectations in prior quarters. Revenue for 2025 was $19.89B with a net income margin of 3.98%, while the P/E ratio stands at 63.48, indicating a premium valuation. Recent news highlights Nokia's strategic pivot to AI-powered networking, including partnerships with Nvidia and telecom providers.
The outlook for NOK is cautiously optimistic, driven by AI and 5G demand, but high valuation and recent earnings miss pose risks. Analyst consensus is a Buy with a $18.00 price target, suggesting significant upside. Key risks include execution on AI initiatives, competitive pressures, and supply chain constraints. The stock's performance hinges on delivering sustained growth from its AI infrastructure investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
